55 related articles for article (PubMed ID: 26319365)
1. Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Clynick B; Tabone T; Fuller K; Erber W; Meehan K; Millward M; Wood BA; Harvey NT
J Mol Diagn; 2015 Nov; 17(6):644-51. PubMed ID: 26319365
[TBL] [Abstract][Full Text] [Related]
2. Squamoproliferative lesions arising in the setting of BRAF inhibition.
Harvey NT; Millward M; Wood BA
Am J Dermatopathol; 2012 Dec; 34(8):822-6. PubMed ID: 22771896
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
4. No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.
Ganzenmueller T; Hage E; Yakushko Y; Kluba J; Woltemate S; Schacht V; Schulz TF; Gutzmer R
Exp Dermatol; 2013 Nov; 22(11):725-9. PubMed ID: 24112647
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
[TBL] [Abstract][Full Text] [Related]
6. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
8. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Landthaler M; Hartmann A; Vogt T
Br J Dermatol; 2009 Mar; 160(3):546-51. PubMed ID: 19076977
[TBL] [Abstract][Full Text] [Related]
10. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
Belum VR; Rosen AC; Jaimes N; Dranitsaris G; Pulitzer MP; Busam KJ; Marghoob AA; Carvajal RD; Chapman PB; Lacouture ME
Cancer; 2015 Jan; 121(1):60-8. PubMed ID: 25186461
[TBL] [Abstract][Full Text] [Related]
11. Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma.
Chang YS; Hsu HT; Ko YC; Yeh KT; Chang SJ; Lin CY; Chang JG
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jul; 118(1):110-116.e1. PubMed ID: 24908601
[TBL] [Abstract][Full Text] [Related]
12. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
14. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
15. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
17. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
18. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
Aksenenko MB; Kirichenko AK; Ruksha TG
Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
Jakubowski M; Hunt JL
Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
[TBL] [Abstract][Full Text] [Related]
20. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
